Literature DB >> 19075049

In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.

Luis A Arroyo, Ingeborg Mateos, Verónica González, Javier Aznar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19075049      PMCID： PMC2650555          DOI： 10.1128/AAC.01097-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  13 in total

1.  In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals.

Authors:  Maria Souli; Flora V Kontopidou; Evangelos Koratzanis; Anastasia Antoniadou; Efthimia Giannitsioti; Pinelopi Evangelopoulou; Sofia Kannavaki; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Reliability of the E-test method for detection of colistin resistance in clinical isolates of Acinetobacter baumannii.

Authors:  L A Arroyo; A García-Curiel; M E Pachón-Ibañez; A C Llanos; M Ruiz; J Pachón; J Aznar
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

3.  Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline.

Authors:  F S Taccone; H Rodriguez-Villalobos; D De Backer; V De Moor; J Deviere; J-L Vincent; F Jacobs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-04       Impact factor: 3.267

4.  In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis.

Authors:  Peter J Petersen; Ponpen Labthavikul; C Hal Jones; Patricia A Bradford
Journal:  J Antimicrob Chemother       Date:  2006-01-23       Impact factor: 5.790

5.  Colistin heteroresistance in acinetobacter and its association with previous colistin therapy.

Authors:  Joshua S Hawley; Clinton K Murray; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

6.  Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report.

Authors:  Anton Y Peleg; Brian A Potoski; Rhonda Rea; Jennifer Adams; Jigme Sethi; Blair Capitano; Shahid Husain; Eun J Kwak; Sunil V Bhat; David L Paterson
Journal:  J Antimicrob Chemother       Date:  2006-11-01       Impact factor: 5.790

Review 7.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

8.  Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline.

Authors:  Kara B Anthony; Neil O Fishman; Darren R Linkin; Leanne B Gasink; Paul H Edelstein; Ebbing Lautenbach
Journal:  Clin Infect Dis       Date:  2008-02-15       Impact factor: 9.079

9.  Synergy testing of multidrug resistant Acinetobacter baumanii against tigecycline and polymyxin using an E-test methodology.

Authors:  M Sands; Y McCarter; W Sanchez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-07       Impact factor: 5.103

10.  Polymyxin-resistant Acinetobacter spp. isolates: what is next?

Authors:  Adriana O Reis; Deise A M Luz; Maria C B Tognim; Hélio S Sader; Ana C Gales
Journal:  Emerg Infect Dis       Date:  2003-08       Impact factor: 6.883
View more
  16 in total

1.  Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii.

Authors:  Brian T Tsuji; Cornelia B Landersdorfer; Justin R Lenhard; Soon-Ee Cheah; Visanu Thamlikitkul; Gauri G Rao; Patricia N Holden; Alan Forrest; Jürgen B Bulitta; Roger L Nation; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

2.  Multidrug-resistant Acinetobacter baumannii: differential adherence to HEp-2 and A-549 cells.

Authors:  Gabrielle Limeira Genteluci; Daniela Betzler Cardoso Gomes; Daniella Pereira; Marta de Campos Neves; Maria José de Souza; Karyne Rangel; Maria Helena Simões Villas Bôas
Journal:  Braz J Microbiol       Date:  2020-03-16       Impact factor: 2.476

Review 3.  Colistin in the 21st century.

Authors:  Roger L Nation; Jian Li
Journal:  Curr Opin Infect Dis       Date:  2009-12       Impact factor: 4.915

Review 4.  Multidrug-resistant Gram-negative infections: what are the treatment options?

Authors:  Helen Giamarellou; Garyphallia Poulakou
Journal:  Drugs       Date:  2009-10-01       Impact factor: 9.546

5.  Effects of colistin and tigecycline on multidrug-resistant Acinetobacter baumannii biofilms: advantages and disadvantages of their combination.

Authors:  Yoshinori Sato; Tsuneyuki Ubagai; Shigeru Tansho-Nagakawa; Yusuke Yoshino; Yasuo Ono
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

Review 6.  Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens.

Authors:  Kyungwon Lee; Dongeun Yong; Seok Hoon Jeong; Yunsop Chong
Journal:  Yonsei Med J       Date:  2011-11       Impact factor: 2.759

7.  Identification of a general O-linked protein glycosylation system in Acinetobacter baumannii and its role in virulence and biofilm formation.

Authors:  Jeremy A Iwashkiw; Andrea Seper; Brent S Weber; Nichollas E Scott; Evgeny Vinogradov; Chad Stratilo; Bela Reiz; Stuart J Cordwell; Randy Whittal; Stefan Schild; Mario F Feldman
Journal:  PLoS Pathog       Date:  2012-06-07       Impact factor: 6.823

8.  In vitro Activity of Colistin in Combination with Tigecycline against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Patients with Ventilator-Associated Pneumonia.

Authors:  Aytekin Cikman; Baris Gulhan; Merve Aydin; Mehmet Resat Ceylan; Mehmet Parlak; Faruk Karakecili; Alper Karagoz
Journal:  Int J Med Sci       Date:  2015-08-14       Impact factor: 3.738

9.  Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients.

Authors:  Ryan K Shields; Cornelius J Clancy; Louise M Gillis; Eun J Kwak; Fernanda P Silveira; Rima C Abdel Massih; Gregory A Eschenauer; Brian A Potoski; M Hong Nguyen
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

10.  Prevalence and Genetic Characterization of Carbapenem- and Polymyxin-Resistant Acinetobacter baumannii Isolated from a Tertiary Hospital in Terengganu, Malaysia.

Authors:  Soo-Sum Lean; Zarizal Suhaili; Salwani Ismail; Nor Iza A Rahman; Norlela Othman; Fatimah Haslina Abdullah; Zakaria Jusoh; Chew Chieng Yeo; Kwai-Lin Thong
Journal:  ISRN Microbiol       Date:  2014-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.